JP2013545816A - インフルエンザウイルス複製阻害物質 - Google Patents

インフルエンザウイルス複製阻害物質 Download PDF

Info

Publication number
JP2013545816A
JP2013545816A JP2013544808A JP2013544808A JP2013545816A JP 2013545816 A JP2013545816 A JP 2013545816A JP 2013544808 A JP2013544808 A JP 2013544808A JP 2013544808 A JP2013544808 A JP 2013544808A JP 2013545816 A JP2013545816 A JP 2013545816A
Authority
JP
Japan
Prior art keywords
alkyl
group
independently
optionally
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013544808A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545816A5 (enExample
Inventor
ポール エス． チャリフソン，
マイケル ピー． クラーク，
ユプル ケー． バンダレージ，
イオアナ デービーズ，
ジョン ピー． ダフィー，
ファイ ガオ，
ジュン フェン，
ジャンリン リャン，
ジョセフ エム． ケネディー，
マーク ダブリュー． レデボア，
ブライアン レッドフォード，
フランソワ マルタイス，
エマニュエル ペローラ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2013545816A publication Critical patent/JP2013545816A/ja
Publication of JP2013545816A5 publication Critical patent/JP2013545816A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013544808A 2010-12-16 2011-12-16 インフルエンザウイルス複製阻害物質 Pending JP2013545816A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42394310P 2010-12-16 2010-12-16
US61/423,943 2010-12-16
US201161527273P 2011-08-25 2011-08-25
US61/527,273 2011-08-25
PCT/US2011/065371 WO2012083117A1 (en) 2010-12-16 2011-12-16 Inhibitors of influenza viruses replication

Publications (2)

Publication Number Publication Date
JP2013545816A true JP2013545816A (ja) 2013-12-26
JP2013545816A5 JP2013545816A5 (enExample) 2015-02-12

Family

ID=45478530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013544808A Pending JP2013545816A (ja) 2010-12-16 2011-12-16 インフルエンザウイルス複製阻害物質

Country Status (10)

Country Link
US (1) US8871774B2 (enExample)
EP (1) EP2651940A1 (enExample)
JP (1) JP2013545816A (enExample)
KR (1) KR20140014110A (enExample)
CN (1) CN103492381A (enExample)
AU (1) AU2011343642A1 (enExample)
CA (1) CA2822057A1 (enExample)
MX (1) MX2013006836A (enExample)
RU (1) RU2013132681A (enExample)
WO (1) WO2012083117A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
JP2019529386A (ja) * 2016-09-05 2019-10-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 抗インフルエンザウイルスのピリミジニル誘導体
JP2021514967A (ja) * 2018-03-05 2021-06-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP2021532149A (ja) * 2018-07-27 2021-11-25 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. インフルエンザウイルス複製阻害剤としてのピロロ［２，３−ｂ］ピリジン誘導体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2442809T3 (en) 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP3068776B1 (en) 2013-11-13 2019-05-29 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
RS57541B1 (sr) 2013-11-13 2018-10-31 Vertex Pharma Postupci za pripremu inhibitora replikacije virusa gripa
MX2017002972A (es) * 2014-09-08 2017-05-30 Janssen Sciences Ireland Uc Pirrolopirimidinas para usarse en la infeccion por el virus de la gripe.
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
HRP20211223T1 (hr) 2015-11-27 2021-11-12 Janssen Sciences Ireland Unlimited Company Heterociklički indoli za upotrebu kod infekcije virusom influence
WO2017097234A1 (en) 2015-12-09 2017-06-15 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
HUE053078T2 (hu) 2016-01-20 2021-06-28 Janssen Sciences Ireland Unlimited Co Aril-szubsztituált pirimidinek influenza vírus fertõzésben való alkalmazásra
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2017133657A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
WO2018033082A1 (en) 2016-08-16 2018-02-22 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109641868B (zh) 2016-08-30 2021-12-03 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2018108125A1 (en) 2016-12-15 2018-06-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108276401B (zh) * 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CN110446711B (zh) 2017-03-02 2022-02-15 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
CN110590768B (zh) * 2018-06-13 2021-02-26 银杏树药业(苏州)有限公司 杂环化合物、其组合物及其作为抗流感病毒药物的应用
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
WO2020150636A1 (en) 2019-01-18 2020-07-23 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
US11820985B2 (en) 2019-03-26 2023-11-21 University Of Massachusetts Modified oligonucleotides with increased stability
US12252487B2 (en) 2019-07-22 2025-03-18 Guangdong Raynovent Biotech Co., Ltd. Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
CA3149835A1 (en) 2019-08-09 2021-02-18 University Of Massachusetts Chemically modified oligonucleotides targeting snps
WO2021047437A1 (zh) * 2019-09-10 2021-03-18 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CN110787170B (zh) * 2019-12-19 2022-06-28 浙江立恩生物科技有限公司 一种治疗流感病毒感染的药物
US12146136B2 (en) 2020-03-26 2024-11-19 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
EP4157289A4 (en) 2020-05-26 2024-06-26 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
CN116323593B (zh) * 2020-10-29 2025-06-03 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) * 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2009525962A (ja) * 2006-01-17 2009-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3829581A (en) * 1970-07-23 1974-08-13 Du Pont Aliphatic polycyclic amidoximes as influenza antiviral agents
IL83821A0 (en) 1986-09-10 1988-02-29 Sandoz Ag Azaindole and indolizine derivatives,their production and pharmaceutical compositions containing them
MX19185A (es) 1989-01-20 1993-12-01 Pfizer Procedimiento para preparar 3-(1,2,5,6-tretrahidropiridil)-pirrolopiridinas.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
DE60011570T2 (de) 1999-01-07 2004-11-25 Wyeth Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (es) 1999-04-22 2003-05-14 Wyeth Corp Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
JP2003503456A (ja) 1999-07-02 2003-01-28 スチュアート エイ． リプトン 神経傷害またはアポトーシスを軽減する方法
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (de) 1999-10-07 2001-04-19 Morphochem Ag Imidazol-Derivate und ihre Verwendung als Arzneimittel
ATE449764T1 (de) 1999-12-28 2009-12-15 Pharmacopeia Inc Cytokine, insbesondere tnf-alpha, hemmer
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
PT1309592E (pt) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc Pirazoles substituidos
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
NZ524682A (en) 2000-09-06 2004-11-26 Ortho Mcneil Pharm Inc A method for treating allergies using substituted pyrazoles
JP2004509897A (ja) 2000-09-22 2004-04-02 イーライ・リリー・アンド・カンパニー シクロヘキシルアミン誘導体の立体選択的製造方法
BR0116323A (pt) 2000-12-22 2003-10-14 Wyeth Corp Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
US20030165873A1 (en) 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system
PT1392697E (pt) 2001-03-14 2005-01-31 Wyeth Corp Antidepressivos derivados aza-heterociclilmetilo de 2,3- di-hidro-1,4-dioxino[2,3-f]quinolina
US6559169B2 (en) 2001-04-24 2003-05-06 Wyeth Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
CA2445543A1 (en) 2001-04-26 2002-11-07 Hong Gao Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-¬1,4|-benzodioxans
US6656947B2 (en) 2001-04-26 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
BR0209408A (pt) 2001-04-26 2004-07-06 Wyeth Corp Antidepressivos de azaheterociclilmetila derivados de 7,8-dihidro-3h-6,9-dioxa-1,3-diaza-ciclopenta[a]naftal eno, método de tratamento usando tais compostos e processo para prepará-los
AU2002256334A1 (en) 2001-04-26 2002-11-11 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino(2,3-f)quinoxaline
JP2004528352A (ja) 2001-04-30 2004-09-16 ワイス 抗うつ作用を持つ７，８−ジヒドロ−１，６，９−トリオキサ−３−アザ−シクロペンタ［ａ］ナフタレンのアザヘテロ環メチル誘導体
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
WO2002092602A2 (en) 2001-05-17 2002-11-21 Wyeth PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
DE60232510D1 (de) * 2001-06-15 2009-07-16 Vertex Pharma 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
JP4370164B2 (ja) 2001-08-14 2009-11-25 富山化学工業株式会社 新規なウイルス増殖阻害・殺ウイルス方法および新規なピラジンヌクレオチド・ピラジンヌクレオシド類似体
US6667322B2 (en) 2001-10-05 2003-12-23 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
AU2003237121A1 (en) 2002-04-26 2003-11-10 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
ES2273043T3 (es) 2002-08-02 2007-05-01 Vertex Pharmaceuticals Incorporated Composiciones de pirazol utiles como inhibidores de gsk-3.
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
WO2004037814A1 (en) 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
CA2517020C (en) 2003-02-26 2012-06-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, method for the production and use thereof in the form of drugs
EP1599475A2 (en) 2003-03-06 2005-11-30 Eisai Co., Ltd. Jnk inhibitors
KR20050122210A (ko) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
CN100569772C (zh) * 2004-03-30 2009-12-16 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
WO2005103050A2 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
KR100476851B1 (ko) 2004-05-18 2005-03-17 (주)성신엔지니어링 중력식 섬유여과기
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
EP2264033A1 (en) 2004-07-27 2010-12-22 SGX Pharmaceuticals, Inc. 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
ES2354824T3 (es) * 2004-11-04 2011-03-18 Vertex Pharmaceuticals, Inc. Pirazolo[1,5-a]pirimidinas útiles como inhibidores de proteínas cinasas.
ZA200704888B (en) 2004-11-22 2009-02-25 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
WO2006063167A1 (en) 2004-12-08 2006-06-15 Smithkline Beecham Corporation 1h-pyrrolo[2,3-b]pyridines
AU2005316540A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1844050B1 (en) 2005-02-03 2009-01-14 Vertex Pharmaceuticals, Inc. Pyrrolopyrimidines useful as inhibitors of protein kinase
BRPI0610828A2 (pt) 2005-05-16 2010-07-27 Irm Llc compostos e composições como inibidores de proteìna quinase
KR20080016659A (ko) 2005-05-20 2008-02-21 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제의 억제제로서 유용한 피롤로피리딘
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
JP2009513571A (ja) 2005-09-30 2009-04-02 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なデアザプリン
AU2007215221C1 (en) 2006-02-14 2013-05-30 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
CA2641254A1 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2648250A1 (en) 2006-04-05 2007-10-18 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of janus kinases
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
CN101646671A (zh) 2006-12-14 2010-02-10 弗特克斯药品有限公司 用作蛋白激酶抑制剂的化合物
NZ577798A (en) 2006-12-21 2012-04-27 Vertex Pharma 5-cyano-4- (pyrrolo [2, 3b] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
WO2008112646A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
ATE526328T1 (de) 2007-03-09 2011-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
WO2008112642A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
JP5087640B2 (ja) 2007-03-22 2012-12-05 武田薬品工業株式会社 Ｐｌｋ１阻害剤として有用な置換ピリミドジアゼピン
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
US8563542B2 (en) 2007-09-28 2013-10-22 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
CN101970465B (zh) 2007-10-09 2016-03-16 欧洲分子生物学实验室(Embl) 能够结合rna帽的流感病毒pb2蛋白可溶性片段
US8173635B2 (en) 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
JP2011513483A (ja) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン
MX2011000021A (es) 2008-06-23 2011-02-24 Vertex Pharma Inhibidores de proteina cinasas.
MX346186B (es) 2008-06-23 2017-03-10 Vertex Pharma Inhibidores de proteina cinasas.
EP2318408B1 (en) 2008-07-23 2016-02-17 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CN102131809A (zh) 2008-07-23 2011-07-20 沃泰克斯药物股份有限公司 三环吡唑并吡啶激酶抑制剂
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CA2731496A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
AU2009274011B2 (en) 2008-07-23 2014-12-18 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2011011653A (es) 2009-05-06 2012-01-20 Vertex Pharma Pirazolopiridinas.
DK2442809T3 (en) * 2009-06-17 2016-12-19 Vertex Pharma Inhibitors of the replication of influenza virus
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
JP2013523884A (ja) 2010-04-14 2013-06-17 アレイ バイオファーマ、インコーポレイテッド ＪＡＫキナーゼの阻害剤としての５，７置換イミダゾ［１，２−ｃ］ピリミジン
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
KR20130128435A (ko) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
CN103492382A (zh) * 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531760A (ja) * 2004-03-30 2007-11-08 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2009525962A (ja) * 2006-01-17 2009-07-16 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017523225A (ja) * 2014-08-08 2017-08-17 ヤンセン・サイエンシズ・アイルランド・ユーシー インフルエンザウイルス感染に使用するためのインドール類
JP2019529386A (ja) * 2016-09-05 2019-10-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 抗インフルエンザウイルスのピリミジニル誘導体
JP2021514967A (ja) * 2018-03-05 2021-06-17 広東衆生睿創生物科技有限公司Ｇｕａｎｇｄｏｎｇ Ｒａｙｎｏｖｅｎｔ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP7031002B2 (ja) 2018-03-05 2022-03-07 広東衆生睿創生物科技有限公司 ピリジノイミダゾール系化合物の結晶型、塩型及びその製造方法
JP2021532149A (ja) * 2018-07-27 2021-11-25 コクリスタル ファーマ, インコーポレイテッドCocrystal Pharma, Inc. インフルエンザウイルス複製阻害剤としてのピロロ［２，３−ｂ］ピリジン誘導体
JP7522722B2 (ja) 2018-07-27 2024-07-25 コクリスタル ファーマ，インコーポレイテッド インフルエンザウイルス複製阻害剤としてのピロロ［２，３－ｂ］ピリジン誘導体
US12357631B2 (en) 2018-07-27 2025-07-15 Cocrystal Pharma, Inc. Pyrrolo[2,3-B]pyridin derivatives as inhibitors of influenza virus replication

Also Published As

Publication number Publication date
US20140005192A1 (en) 2014-01-02
US8871774B2 (en) 2014-10-28
EP2651940A1 (en) 2013-10-23
MX2013006836A (es) 2013-09-26
KR20140014110A (ko) 2014-02-05
WO2012083117A1 (en) 2012-06-21
RU2013132681A (ru) 2015-01-27
CA2822057A1 (en) 2012-06-21
CN103492381A (zh) 2014-01-01
AU2011343642A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US10875855B2 (en) Inhibitors of influenza viruses replication
US8871774B2 (en) Inhibitors of influenza viruses replication
DK3141252T3 (en) INHIBITORS OF INFLUENZA VIRUS REPLICATION
JP2013545818A (ja) インフルエンザウイルス複製阻害物質
JP2013545817A (ja) インフルエンザウイルス複製阻害物質
WO2013184985A1 (en) Inhibitors of influenza viruses replication
HK1190699A (en) Inhibitors of influenza viruses replication
HK1193810A (en) Inhibitors of influenza viruses replication
HK1190700A (en) Inhibitors of influenza viruses replication
OA17028A (en) Inhibitors of influenza viruses replication.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160510